Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
January 4, 2017 4:00 AM 4 min read

Waters CE-Marks In Vitro Diagnostic MassTrak Vitamin D Solution

by Business Wire
Follow
WAT Logo
WATWaters Corp
$328.66-%
Overview
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Press Releases
MILFORD, Mass.--(BUSINESS WIRE)--

Waters Corporation (NYSE: WAT) announced today that its fully-validated Waters® MassTrak™ Vitamin D Solution is now CE-marked in accordance with IVD Directive 98/79/EC for the quantitative measurement of 25(OH) D2 and D3 (25-OH-VitD) from human plasma and serum. The IVD LC-MS/MS system solution is a complete solution consisting of reagents and consumables, instrumentation, and software and support services for clinical laboratories routinely measuring vitamin D in patient samples*. The Vitamin D solution is currently only available for sale in Europe.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170104005422/en/

Waters CE-Marks In Vitro Diagnostic MassTrak Vitamin D Solution (Photo: Business Wire)

"Our MassTrak Vitamin D Solution is the first, CE-marked, single-vendor system to measure both vitamins 25(OH) D2 and D3 independently and accurately from human plasma and serum in a single analysis," said Jose Castro-Perez, Ph.D., Director of Health Sciences, Global Marketing Operations, Waters Corporation. "It's the ideal solution for clinical laboratories performing (25-OH-VitD) analysis on a routine basis and which may want to standardize (25-OH-VitD) analysis on a single-vendor platform."

Vitamin D, the main source of which is from dietary intake, is part of a family of fat-soluble secosteroids and has two major forms - ergocalciferol (plant derived Vitamin D2) and cholecalciferol (animal derived Vitamin D3). Vitamin D is also derived from the conversion of 7-dihydrocholesterol to Vitamin D3 following exposure of skin to sunlight. Increasingly, research is revealing the importance of vitamin D in protecting against a host of health problems. In the absence of vitamin D, bones can become brittle and thin. The research also suggests that vitamin D plays a role in modulating cell growth, the function of neuromuscular and immune systems, and reducing inflammation. It also indicates that those most at risk of a vitamin D deficiency are those who shun the sun, have milk allergies, adhere to a strict vegan diet, or suffer from certain diseases.

Due, in part, to mounting evidence of the importance of vitamin D to human health and to news media coverage, Medicare reimbursement volumes of vitamin D laboratory tests rose 83-fold from 2000 – 20101.

The MassTrak Vitamin D Solution is configured with the Waters ACQUITY UPLC® I-Class/ Xevo® TQD IVD System, the MassTrak Vitamin D Kit and MassLynx® (IVD) Mass Spectrometry Software. The MassTrak Vitamin D Kit provides metrological traceability to the National Institute of Standards and Technology (NIST) Standard Reference Material (SRM) 2972, enabling standardization and lot- to-lot consistency for an easy comparison of results from multiple laboratories. For high-volume vitamin D testing, the system is designed for use with an automated liquid handler and custom pipetting script provided with the kit.

LC-MS/MS in the Clinical Laboratory

In pursuit of better accuracy and precision for clinical laboratory analyses, liquid chromatography tandem mass spectrometry (LC-MS/MS) is rapidly becoming the analytical technique of choice. Waters IVD LC-MS/MS medical devices provide clinical laboratories access to technologies delivering selectivity, sensitivity and versatility – performance characteristics that traditional methods, such as immunoassays, often struggle to meet.

Designed to optimize workflow from pre-analytics to post-analytics, our system portfolio offers a wide variety of options for the routine use of LC-MS/MS in the clinical laboratory.

For more information: www.waters.com/vitamind

About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT) develops and manufactures advanced analytical and material science technologies for laboratory dependent organizations. For more than 50 years, the company has pioneered a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis systems.

*For in vitro diagnostic use. Not available for sale in all countries.

1. Arch Pathol Lab Med. 2014 February ; 138(2): 189–203. doi:10.5858/arpa.2013-0149-OA

Waters, UPLC, ACQUITY, ACQUITY UPLC, Xevo, MassLynx and MassTrak are trademarks of Waters Corporation.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005422/en/

Waters Corporation:
Brian J. Murphy, +1 508-482-2614
Public Relations
[email protected]

WAT Logo
WATWaters Corp
$328.66-%
Overview
Comments
Loading...